Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction-Reference-Cited by-同舟云学术

Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction

Published:2022-10 Issue:4 Volume:227 Page:618.e1-618.e16
ISSN:0002-9378
Container-title:American Journal of Obstetrics and Gynecology
language:en
Short-container-title:American Journal of Obstetrics and Gynecology

Author:

Agrawal Swati,Parks W. Tony,Zeng Helen Dehui,Ravichandran Anjana,Ashwal Eran,Windrim Rory C.,Hobson Sebastian R.,Melamed Nir,Kingdom John C.^ORCID

Funder

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference54 articles.

1. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation;Brosens;Am J Obstet Gynecol,2011

2. Punch biopsy of the human placental bed;Robson;Am J Obstet Gynecol,2002

3. The placental basis of fetal growth restriction;Zur;Obstet Gynecol Clin North Am,2020

4. T2∗ placental magnetic resonance imaging in preterm preeclampsia: an observational cohort study;Ho;Hypertension,2020

5. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction;McLaughlin;Am J Obstet Gynecol,2022

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of placental biomarkers and fetoplacental Dopplers in predicting likely placental pathology in early and late fetal growth restriction – A prospective study;Placenta;2024-10

2. Enhancing the Retinopathy Of Prematurity Risk Profile Through Placental Evaluation of Maternal and Fetal Vascular Malperfusion;Investigative Ophthalmology & Visual Science;2024-09-04

3. Umbilical–portal–systemic venous shunt and intrauterine growth restriction: an inquiry from a prospective study;American Journal of Obstetrics and Gynecology;2024-09

4. Does the use of angiogenic biomarkers for the management of preeclampsia and fetal growth restriction improve outcomes?: Challenging the current status quo;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

5. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing;American Journal of Obstetrics and Gynecology;2024-09